The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.
May 13th 2024
These options are typically more cost-effective, enhancing patient accessibility
Study: Genentech’s Herceptin Lost Market Share After Introduction of First Trastuzumab Biosimilar
June 29th 2023Investigators found that the first biosimilar of trastuzumab, trastuzumab-anns (Kanjinti; Amgen), did maintain a strong and persistent advantage over the other 4 biosimilar entrants.
Read More
Ensuring Innovation Act Changes Eligibility for New Chemical Exclusivity
Law aims to encourage competition in the pharmaceutical industry, making it easier for generics to enter market.
Read More
Pegfilgrastim Biosimilar for Treatment of Neutropenia Launches
May 17th 2023Pegfilgrastim-pbbk is a leukocyte growth factor developed to reduce the onset of infection in patients with non-myeloid malignancies administered myelosuppressive anticancer medications associated with a clinically significant rate of febrile neutropenia.
Read More
Expert: Though Patients Don’t Always See Savings With Biosimilars, New Policies Could Improve Access
May 15th 2023Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the role biosimilars are playing in the pharmaceutical market as well as in patient access.
Watch
Expert: Pharmacy, Medical Benefit Adoption of Biosimilars Present Different Challenges
May 2nd 2023Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the biosimilars landscape and where biosimilars fall in the process of pharmacy and medical benefit adoption.
Watch